PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
175.10%
G&A growth while AVXL reduces overhead. John Neff would investigate operational differences.
No Data
No Data available this quarter, please select a different quarter.
-94.58%
Other expenses reduction while AVXL shows 683.33% growth. Joel Greenblatt would examine efficiency.
-14.44%
Both companies reducing operating expenses. Martin Whitman would check industry trends.
-14.44%
Both companies reducing total costs. Martin Whitman would check industry trends.
4.10%
Interest expense growth less than half of AVXL's 683.33%. David Dodd would verify sustainability.
No Data
No Data available this quarter, please select a different quarter.
14.44%
EBITDA growth below 50% of AVXL's 33.02%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
14.44%
Operating income growth 50-75% of AVXL's 26.75%. Martin Whitman would scrutinize operations.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Both companies reducing other expenses. Martin Whitman would check industry patterns.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.51%
Tax expense reduction while AVXL shows 0.00% growth. Joel Greenblatt would examine advantage.
12.51%
Net income growth below 50% of AVXL's 25.65%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
12.37%
EPS growth below 50% of AVXL's 26.32%. Michael Burry would check for structural issues.
12.37%
Diluted EPS growth below 50% of AVXL's 26.32%. Michael Burry would check for structural issues.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.